NEW YORK, August 8, 2018 /PRNewswire/ --
CannabisNewsWire Editorial Coverage
In a landmark announcement, the U.S. Food and Drug Administration (FDA) recently approved a drug derived from pure cannabidiol (CBD), Epidiolex, to treat seizures associated with certain forms of severe epilepsy, setting the stage for huge changes in the world of cannabidiol (CBD).
- FDA approval of a cannabis-based drug represents seismic political, legal and economic shifts
- Approval likely will lead to more clinical research and further validation of CBD therapeutic efficacy
- CBD market projected to explode to more than $2 billion in two years with 39 percent CAGR
What's most transformative about this drug approval is that this is the first time the FDA - the governmental arbiter of safe and effective medicine in the United States - has approved any substance derived from the cannabis sativa plant and validated certain therapeutic benefits of cannabidiol. The FDA is, to some extent, endorsing what has been anecdotally accepted by the masses for millennia.
CBD, a non-psychoactive cannabinoid that can be extracted from the industrial hemp plant, is understandably generating worldwide interest from both the scientific and investment communities. A large part of CBD's mass appeal is that it's believed to aid with a broad range of wellness concerns. CBD is known to interact with the human endocannabinoid system, which is found throughout the body's nervous system, organs, connective tissues, glands and immune system. Research indicates CBD may have the potential to treat a wide range of conditions such as anxiety, high blood pressure, skin issues, and chronic pain. It's being researched to treat Alzheimer's, and one study even suggests CBD might be a useful addition when given with conventional antipsychotic medications in the treatment of schizophrenia.
Continued rigorous clinical research is being conducted to further confirm all the potential therapeutic benefits that may be found in this cannabinoid extract. In the meantime, the mass appeal of CBD remains unabated, and the market for CBD products continues to grow at an astounding rate. Committed to the legal hemp-derived CBD market , Marijuana Company of America, Inc. (OTC:MCOA) (MCOA Profile) provides consumers with pure, hemp plant-based CBD nutritional products through its global hempSMART™ brand and has initiated broad-ranging, innovative cultivation programs for legal, high-quality hemp. Others vying for position in the burgeoning CBD space include Isodiol International, Inc. (CSE:ISOL) (OTC:ISOLD) (FSE: LB6A.F), CV Sciences, Inc. (OTC:CVSI), PotNetwork Holdings, Inc. (OTC:POTN) and Medical Marijuana, Inc. (OTC:MJNA).
The Boom Has Just Begun
Three years ago, in 2015, the hemp-derived CBD market racked up $90 million in sales. Last year that number reached $190 million in sales - and the boom has just begun. The Hemp Business Journal projects $2.1 billion in total CBD sales by 2020 and estimates that $450 million of that will come from hemp-based sources. The explosive demand projections are attributed to an increased public awareness of the wide-ranging potential health benefits of hemp CBD oil and advancements in cultivation, plus the convenience and reach of online retailing - all of which contribute to a global CBD oil market expected to grow at an eye-popping CAGR of 39.19 percent through 2021.
With an overarching focus on the cultivation, development and distribution of legal industrial hemp-derived products, Marijuana Company of America (OTC: MCOA) aims to capture an outsized share of growing worldwide demand. Pure hemp-based consumer nutritional products are at the core of this demand, and the company has developed a portfolio of ancillary hemp-centric businesses to vertically integrate hemp production and sales. Cultivation of high-quality hemp from portfolio companies feeds MCOA's proprietary CBD-based formulations, dovetailing to produce the finest quality nutritional supplements on the market.
The unique company vision emanates from Donald Steinberg, MCOA's CEO. A cannabis industry pioneer, he founded the first cannabinoid-centric company to trade on a U.S. stock market. His vast knowledge and industry experience give MCOA unparalleled insights into the machinations of the CBD markets and the vision to capitalize on industry opportunities in a market projected to exceed $2 billion in the coming years. In keeping with this ambitious strategy, Steinberg and his partner, Charlie Larsen, formed Marijuana Company of America as well its sister company, Canadian-based Global Hemp Group, Inc., which is focused on the legal cultivation and processing of industrial hemp. MCOA continues to build an impressive portfolio of synergistic companies across the hemp spectrum. From farm to finished products, MCOA's socially conscious strategy is to capitalize at each profit point and establish a significant footprint at multiple inflection points across the entire hemp value chain.
MCOA has worked to create a recognized and respected hempSMART product line that contains levels of clinically researched ingredients designed to exceed consumer expectations and support the body's natural endocannabinoid system. To serve health-conscious consumers, hempSMART includes an array of proprietary nutritional products.
- hempSMART Brain is a patent-pending formulation designed for optimal brain function support.
- hempSMART Drops offer the highest concentration and potency of full-spectrum bioavailable CBD.
- hempSMART Pain Capsules contain a blend of premium CBD and botanical supplements.
- hempSMART Pain Cream is a proprietary formulation for relief from muscle and joint pain.
- hempSMART Full Spectrum Pet Drops is a unique nutritional supplement designed for furry family members.
- hempSMART Face is a topical face moisturizer that combines CBD oil with ayurvedic herbs and botanicals.
MCOA's hempSMART goes through an exacting CO2 extraction process to ensure the highest quality in the company's natural wellness product line. By combining these pure industrial hemp-based cannabinoids with some of nature's most effective wellness ingredients, MCOA's hempSMART products are poised to deliver optimally formulated wellness products to health-conscious consumers.
In a forward-thinking plan to expand retail distribution and capitalize on impulse buys in high-traffic stores, MCOA took a 25 percent equity stake in BeniHemp-branded CBD products. BeniHemp health-focused products include topicals, tinctures and edibles packaged in one-day, two-day and thirty-day supplies widely distributed to convenience stores, smoke shops, gas stations and small retail outlets.
A Growing Portfolio
In addition to the hempSMART and BeniHemp consumer products lines, MCOA continues to strategically assemble synergistic portfolio companies. In a joint venture with sister company Global Hemp Group, MCOA launched a 125-acre industrial hemp cultivation project in northeast New Brunswick, Canada. The project targets the promotion of hemp farming while providing year-round jobs in crop and finished product processing.
Also in conjunction with Global Hemp Group, MCOA is developing Covered Bridge Acres, an innovative high-yielding CBD hemp cultivation project in Oregon. The project utilizes both traditional outdoor cultivation and what will ultimately become more than 19,000 square feet of indoor greenhouses, which are slated to eventually supply the raw oil needed for the hempSMART CBD product line.
MCOA also took a 15 percent equity stake in MoneyTrac Technology, Inc., a subsidiary of Global Payout, Inc. . MCOA made this investment to help establish and market MoneyTrac Technology as an alternative banking solution for the cannabis industry.
Others Vying for Position
Isodiol International, Inc. (CSE: ISOL) (OTCQB: ISOLD) (FSE: LB6A.F) grows and harvests hemp on an industrial scale then processes it to extract the cannabidiol for distribution. The company commercializes pharmaceutical-grade cannabinoids, micro-encapsulations and nanotechnology for consumable and topical skin care products. Isodiol has announced plans to develop additional over-the-counter and pharmaceutical drugs, expand its phytoceutical portfolio and expand into Latin America, Asia and Europe.
CV Sciences, Inc. (OTCQB:CVSI) operates in two business segments. The company's drug development division develops and commercializes novel therapeutics utilizing synthetic CBD. Its consumer product division manufactures, markets and sells plant-based CBD products to a range of market sectors. The company is also developing and pursuing FDA approval for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient.
Founded by MCOA CEO Donald Steinberg in 2009, Medical Marijuana, Inc. (OTC:MJNA) was the first U.S.-traded CBD company. The company develops, distributes and sells hemp oil that contains naturally occurring cannabinoids, including CBD. The company sells its hemp-derived CBD products through a variety of distribution subsidiaries. The company was among the first to bring hemp-based CBD oil products to market in the United States and the first to receive federal government import approvals in Mexico, Paraguay and Brazil.
PotNetwork Holdings, Inc. (OTC:POTN) is a publicly traded company that acts as a holding company for its subsidiaries, First Capital Venture Co.; Diamond CBD, Inc.; and Sunrise Auto Mall, Inc. Diamond CBD focuses on the research, development and multinational marketing of hemp extracts that contain a broad range of cannabinoids and natural hemp derivatives. Diamond CBD's team consists of hemp industry professionals, chemists, doctors and scientists - all working together to produce CBD oils.
Modern science has begun to substantiate both the anecdotal history and the therapeutic efficacy of cannabidiol. The FDA's recent approval of a cannabis-based drug represents a seismic shift and is further indication of the enormous curative potential that may be found in CBD. As more scientific validations ensue, the market for CBD products could easily exceed expectations, and well-positioned companies in the space could outperform the market.
For more information about Marijuana Company of America, please visit Marijuana Company of America (OTC:MCOA).
(CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
Receive Text Alerts from CannabisNewsWire: Text "Cannabis" to 21000
For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News
DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with CNW or any company mentioned herein. The commentary, views and opinions expressed in this release by CNW are solely those of CNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW and FNM for any investment decisions by their readers or subscribers. CNW and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.
CNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and CNW and FNM undertake no obligation to update such statements.
CannabisNewsWire (CNW) & NetworkNewsWire (NNW) are proud to be affiliated partners of the Investor Brand Network (IBN)
Over the past 10+ years we have consistently introduced new network brands, each specifically designed to fulfil the unique needs of our growing client base and services. Today, we continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Please feel free to visit the Investor Brand Network (IBN) http://www.InvestorBrandNetwork.com
Corporate Communications Contact:
FN Media Group, LLC